BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 3711961)

  • 1. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types).
    Bernstein JI; Coleman CN; Strickler JG; Dorfman RF; Rosenberg SA
    J Clin Oncol; 1986 Jun; 4(6):847-58. PubMed ID: 3711961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
    J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
    Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
    J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
    Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt's lymphomas in adult patients.
    Jost LM; Jacky E; Dommann-Scherrer C; Honegger HP; Maurer R; Sauter C; Stahel RA
    Ann Oncol; 1995 May; 6(5):445-51. PubMed ID: 7545428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults.
    Magrath IT; Janus C; Edwards BK; Spiegel R; Jaffe ES; Berard CW; Miliauskas J; Morris K; Barnwell R
    Blood; 1984 May; 63(5):1102-11. PubMed ID: 6546890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burkitt's lymphoma in the base of the tongue: differential diagnosis and management.
    Manolopoulos L; Nikolopoulos TP; Yiotakis J; Karapatsas J; Maris A; Ferekidis E
    ORL J Otorhinolaryngol Relat Spec; 2003; 65(4):226-9. PubMed ID: 14564099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
    Ribrag V; Koscielny S; Bosq J; Leguay T; Casasnovas O; Fornecker LM; Recher C; Ghesquieres H; Morschhauser F; Girault S; Le Gouill S; Ojeda-Uribe M; Mariette C; Cornillon J; Cartron G; Verge V; Chassagne-Clément C; Dombret H; Coiffier B; Lamy T; Tilly H; Salles G
    Lancet; 2016 Jun; 387(10036):2402-11. PubMed ID: 27080498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.
    Thomas DA; Cortes J; O'Brien S; Pierce S; Faderl S; Albitar M; Hagemeister FB; Cabanillas FF; Murphy S; Keating MJ; Kantarjian H
    J Clin Oncol; 1999 Aug; 17(8):2461-70. PubMed ID: 10561310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Burkitt's lymphoma: single-centre experience with modified BFM protocol.
    Harris E; Paneesha S; Jackson N; Jones L; Mahendra P
    Clin Lab Haematol; 2002 Apr; 24(2):111-4. PubMed ID: 11985557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced stage (III-IV) Burkitt's lymphoma and B-cell acute lymphoblastic leukaemia in children: kinetic and pharmacologic rationale for treatment and recent results (1979-1983).
    Murphy SB; Bowman WP; Hustu HO; Berard CW
    IARC Sci Publ; 1985; (60):405-18. PubMed ID: 3905592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
    Schwenn MR; Blattner SR; Lynch E; Weinstein HJ
    J Clin Oncol; 1991 Jan; 9(1):133-8. PubMed ID: 1985162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Hodgkin's lymphoma protocols in the treatment of patients with Burkitt's lymphoma and lymphoblastic lymphoma: a report on 58 patients.
    Kaiser U; Uebelacker I; Havemann K
    Leuk Lymphoma; 1999 Dec; 36(1-2):101-8. PubMed ID: 10613454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas.
    Adde M; Shad A; Venzon D; Arndt C; Gootenberg J; Neely J; Nieder M; Owen W; Seibel N; Wilson W; Horak ID; Magrath I
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):33-9; discussion 45-8. PubMed ID: 9578060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-intensity therapy in adults with Burkitt's lymphoma.
    Dunleavy K; Pittaluga S; Shovlin M; Steinberg SM; Cole D; Grant C; Widemann B; Staudt LM; Jaffe ES; Little RF; Wilson WH
    N Engl J Med; 2013 Nov; 369(20):1915-25. PubMed ID: 24224624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD).
    Skarin AT; Canellos GP; Rosenthal DS; Case DC; MacIntyre JM; Pinkus GS; Moloney WC; Frei E
    J Clin Oncol; 1983 Feb; 1(2):91-8. PubMed ID: 6199472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.